Hematologist
CION Cancer Clinics
Waiting for molecular results before starting treatment | CION Cancer Clinics
In acute leukaemia, treatment often starts before the genetic results are back, because waiting can be more dangerous than starting. In slower blood cancers such as CLL, many lymphomas and myeloma, the team usually waits, because the results may change which medicine is chosen. Either way, the gene results still shape the plan when they arrive. This guide explains how that decision is made. At CION Cancer Clinics, our haematologist reviews abnormal blood reports with you, orders only the tests that answer your question and explains each result plainly.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Should treatment start before the genetic results are back?
- When does the team usually start, and when does it usually wait?
- How does the team decide whether to wait?
- What can the genetic results change once treatment has begun?
- What do families often worry about with this decision?
- What should you ask before agreeing to start or wait?
- Common questions about starting before genetic results
The short answer
Should treatment start before the genetic results are back?
In acute leukaemia, treatment often starts before the genetic results arrive, because waiting can be more dangerous than starting. In slower blood cancers, the team usually waits, because a short delay rarely changes the outcome and the results may change the choice of treatment.
Why acute leukaemia often cannot wait
Acute leukaemia can crowd out the healthy marrow quickly. Counts fall, infections and bleeding become more likely, and some people become very unwell within days. The first phase of treatment is similar for many types, so the team can begin once the microscope and flow cytometry confirm the diagnosis.
Why slower blood cancers usually wait
Chronic lymphocytic leukaemia, many lymphomas, myeloma and myelodysplastic syndrome often allow time for the full picture. In these, a gene result such as a TP53 change can decide which medicine is chosen. Starting the wrong one first is harder to undo than a short, planned wait.
What this page cannot decide for you
Only your treating haematologist can weigh how unwell you are against what the pending tests might change. Two people with the same diagnosis may get different advice for good reasons. Use this page to understand the thinking and to ask better questions, not to press for a start or a delay.
Side by side
When does the team usually start, and when does it usually wait?
Usually starts before the results
Usually waits for the results
Acute leukaemia with falling counts or infection
Stable chronic leukaemia found on a routine test
Suspected acute promyelocytic leukaemia (APL)
Myelodysplastic syndrome without urgent symptoms
Very high white cell count causing symptoms
Slow-growing lymphoma being watched
Kidney or other organ strain from the disease
A choice between medicines that depends on a gene result
Not sure whether this applies to you?
Ask an oncologistBehind the decision
How does the team decide whether to wait?
How unwell are you now?
Blood counts, infection, bleeding and organ function are checked first. If these are getting worse, the balance tips towards starting treatment without delay.
What is already certain?
The microscope and flow cytometry results usually confirm the type of blood cancer. That is often enough to choose the first phase of treatment safely.
What could the pending test change?
If a gene result would only affect later treatment, starting now makes sense. If it would change the very first medicine, waiting a little may be wiser.
How long is the wait?
The team checks when each result is expected and whether an urgent single-gene test can be run faster than the full panel. A wait of a few days is weighed very differently from an open-ended one.
When results arrive
What can the genetic results change once treatment has begun?
Starting early does not throw away the results. They are built into the plan as they arrive.
A targeted medicine is added
Some gene changes have a matching medicine that can be added to the treatment already under way.
Examples
- FLT3 changes in AML
- BCR-ABL1 in some ALL
The risk group is set
The results place the leukaemia in a favourable, intermediate or adverse group. This shapes what follows the first phase, such as how many further courses of chemotherapy are planned, or whether more intensive treatment is needed.
A transplant is discussed
An adverse result may lead the team to start a transplant conversation and a donor search early, with a partner centre.
CION does not perform transplants. The team helps coordinate referral.The diagnosis is refined
Occasionally the gene or chromosome result changes the exact diagnosis, and the plan is adjusted to match it. The team will explain what changed and why, and what it means for the treatment already given.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often worry about with this decision?
"Starting before all the results means the doctors are guessing."
The diagnosis is usually already confirmed. What is pending is the fine detail that shapes later steps. Starting the first phase is a considered decision, not a guess. It is built to suit the likely gene results, and it can be changed if a result points another way.
"Waiting for results means the doctors are not taking it seriously."
In slower blood cancers, a planned wait lets the team choose the right medicine first. Your counts and symptoms are still watched closely during that time. If anything worsens, the plan can move forward without waiting for the last report.
"If we go elsewhere, they will start sooner."
Moving hospitals mid-workup often means repeating tests and waiting longer. If you want another view, ask for your reports and slides to be reviewed without restarting the process.
"Once treatment starts, the gene results no longer matter."
They matter a great deal. They decide whether to add a targeted medicine, what follows the first phase and whether a transplant should be considered.
Did you know
In acute promyelocytic leukaemia, a vitamin A-based medicine is often started as soon as the disease is suspected, before genetic confirmation, because early treatment lowers the risk of serious bleeding.
Being straight with you
What should you ask before agreeing to start or wait?
Ask what is already known, what is still pending, and what each pending result could change. Those three answers usually make the decision clear. Write them down, because the first days after a diagnosis move quickly and much of what is said is easy to forget. If a family member is making decisions with you, make sure they hear the same explanation.
If treatment is starting now
Ask which results are still awaited and when they are expected. Ask whether any of them could add a medicine or change the plan after the first phase. Ask whom to call if you have not heard by that date.
If the team suggests waiting
Ask how long the wait is likely to be and what will be checked in the meantime. Ask which symptoms mean you should come in sooner. Fever, bleeding, severe breathlessness or confusion never wait for a report. Go to the nearest emergency department or call 108.
If you are unsure
It is reasonable to ask for the reasoning to be explained again, with a family member present. At CION, the haematology team discusses these cases at a tumour board, so the decision to start or wait reflects more than one doctor's view. Please do not start, stop or delay any medicine on your own while results are pending.
Questions we are asked
Common questions about starting before genetic results
Will starting early harm the genetic test results?
Usually not, because the samples for genetic tests are taken before treatment begins. That is why the team collects enough marrow and blood at the first procedure. If a test needs to be repeated later, treatment can make it harder to read, so ask whether all samples were sent.
Can a targeted medicine be added after chemotherapy has started?
Often yes. For example, if a FLT3 change is found in AML, a matching targeted medicine can be added during the first phase. The timing and choice are decided by your haematologist, based on your results and how you are coping with treatment.
What if the results change the diagnosis after we start?
It is uncommon, but it happens. The team reviews the new result, explains what it means and adjusts the plan. The first phase is usually chosen so that it is reasonable across the likely possibilities, which limits the effect of a late change.
Is waiting ever risky in a slower blood cancer?
It can be if symptoms worsen, so the team keeps checking counts and how you feel during the wait. If things change, they may start sooner. Tell them about new fever, bleeding, weight loss or rapidly growing lumps rather than waiting for the next visit.
Can we pay extra for faster genetic results?
Some laboratories offer faster reporting for specific urgent tests, sometimes at added cost. Whether it helps depends on whether the result would change today's decision. Ask your haematologist which result matters most right now before paying for speed.
Does this apply to children with leukaemia?
Yes, in a similar way. Children with acute lymphoblastic leukaemia usually start treatment once the diagnosis is confirmed, and genetic and early response results then decide how intensive later treatment should be. The team treating your child will explain each step.
Will insurance or schemes cover treatment before the full report?
Usually coverage follows the confirmed diagnosis, which the microscope and flow results often provide. Aarogyasri, PM-JAY, CGHS, ECHS, EHS and cashless insurers each have their own rules, and these change. Check the current rules with the scheme desk or your insurer early.
Should we get a second opinion before starting?
In a slower blood cancer, there is often time for one. In acute leukaemia, ask whether a review can happen alongside treatment rather than instead of it. Sending reports and slides for review is usually faster than a fresh workup.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Acute Myeloid Leukemia (AML)
- Cancer Research UK — Acute myeloid leukaemia (AML)
- Leukemia & Lymphoma Society — Acute Myeloid Leukemia
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
How Long Haematology Results Take, Test by TestWhen each pending result is likely to arriveMyeloid NGS Panels: What Gets Tested and WhyThe gene panel most often being waited onRisk Stratification: Favourable, Intermediate, AdverseWhat the results decide once they arriveSecond Opinion on a Haematology Marrow ReportGetting another view without restarting the workup
Talk to us
Unsure whether to start or wait?
Share your reports or call the helpline. The haematology team will explain what is known, what is pending and what it could change.